Ocugen (OCGN) announced that Bob Smith, former Senior Vice President, Global Gene Therapy Business at Pfizer (PFE), has joined the Company’s Business Advisory Board. The BAB was established in June 2023 to assist in driving public/private partnerships with governments around the world; pursuing business collaborations, partnerships, and licensing opportunities; creating awareness of the Company’s differentiated capabilities; and promoting access to the Company’s therapies around the world.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OCGN:
- Biotech Alert: Searches spiking for these stocks today
- Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design
- Ocugen gains FDA alignment on key aspects of OCU400 Phase 3 trial
- Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations
- Ocugen announces FDA granted RMAT designation to OCU400
